Repligen posts Q3 2026 earnings beat, raises full‑year outlook and highlights BioLife acquisition
Repligen reported third‑quarter 2026 revenue of $209.3 million, up 10.9% year over year, and a GAAP loss of $38.4 million that included a $41.2 million intangible‑asset impairment, resulting in diluted EPS of $(0.68). On an adjusted basis the company earned $0.53 per share and generated $43.84 million of adjusted EBITDA. Management lifted its full‑year revenue guidance to $848 million and its adjusted EPS outlook to $2.07, citing growth in proteins and chromatography and the recent BioLife acquisition. Analysts reiterated buy ratings, with Stifel keeping a $207 price target and Canaccord maintaining a hold with a $180 target.
Why it matters
The raised guidance signals higher expected cash flow and profitability for the year, which may support a higher valuation for investors. Analyst coverage remains positive, with Stifel’s $207 target implying roughly 17% upside from the current price.
Key facts
- 1Q3 2026 revenue was $209.3 million, a 10.9% year‑over‑year increase. tradingview.com
- 2GAAP net loss was $38.4 million, including a $41.2 million intangible‑asset impairment charge. tradingview.com
- 3Diluted GAAP EPS was $(0.68), versus $0.26 a year earlier. tradingview.com
- 4Adjusted EPS was $0.53, beating the $0.46 estimate. finance.yahoo.com
- 5Adjusted EBITDA was $43.84 million. finance.yahoo.com
- 6Full‑year revenue guidance was raised to $848 million at the midpoint. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.